Trial Profile
Randomized, double blind, placebo controlled, multicenter pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary)
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms EMPA-RESPONSE
- 29 Nov 2020 Results published in the European Journal of Heart Failure
- 07 Jan 2020 Primary endpoint has not been met. (Plasma NTproBNP)
- 07 Jan 2020 Primary endpoint has not been met. (Length of Stay)